To explore the role of neurotrophin-3 (NT-3) during cerebral ischemia, NT-3-deficient brains were subjected to transient focal ischemia. Conditional mutant brains produced undetectable amounts of NT-3 mRNA, whereas the expression of the neurotrophin, BDNF, the NT-3 receptor, TrkC, and the nonselective, low-affinity neurotrophin receptor p75NTR, were comparable to wild-type. Baseline absolute blood flow, vascular and neuroanatomical features, as well as physiological measurements were also indistinguishable from wild-type. Interestingly, the absence of NT-3 led to a significantly decreased infarct volume 23 h after middle cerebral artery occlusion. Consistent with this, the addition of NT-3 to primary cortical cell cultures exacerbated neuronal death caused by oxygen-glucose deprivation. Coincubation with the oxygen free radical chelator, trolox, diminished potentiation of neuronal death. NT-3 also enhanced neuronal cell death and the production of reactive oxygen species caused by oxidative damage inducing agents. We conclude that endogenous NT-3 enhanced neuronal injury during acute stroke, possible by increasing oxygen-radical mediated cell death.
INTRODUCTION
The neurotrophin family of growth factors, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5), have a wide spectrum of effects on developing and mature neurons of the central and peripheral nervous systems. Classically, neurotrophins are thought of as neuronal survival factors that prevent the developmentally programmed death of peripheral neurons or the experimentally induced death of central neurons (Lewin and Barde, 1996) .
Given their role as neuronal survival factors, much attention has focused on neurotrophin involvement in models of central nervous system injury, like cerebral ischemia. After an ischemic event, BDNF and NGF mRNA were found to increase, whereas NT-3 mRNA decreased in dentate gyrus, a region of the brain relatively resistant to ischemic cell death (Lindvall et al., 1 These two authors contributed equally to this work. 2 To whom correspondence and reprint requests should be addressed at present address: Genetics Institute Inc., 35 Cambridge Park Drive, Cambridge, MA, 02140. Fax:(617) 
